Portrait of a woman with curly brown hair wearing a dark denim shirt, standing in front of an orange background.

Enabling the next era of informed cancer care

Exact Sciences delivers the promise and value of precision medicine with the Oncotype DX® test.

The Oncotype DX Breast Recurrence Score® test – bringing clarity to treatment decisions:

Uniquely designed

Uniquely designed to help identify patients who need chemotherapy1-3

Gold Standard

The gold standard to avoid over- and undertreatment4-7

High quality testing

High quality testing in a centralised laboratory with a short time to result8

What is the Oncotype DX test video.
How Oncotype DX works and how it can help guide a tailored chemotherapy treatment decision for your HR+, HER2-, early-stage breast cancer patients

Oncotype DX Test results trusted by many worldwide

1.5 million
patients tested8
90+
countries served8
Highest level of evidence
Recommended by all International Guidelines4-7,9-14
Picture of the Oncotype DX package

Oncotype DX
Breast Recurrence Score®

The only multigene assay proven to predict a patient’s individual benefit from chemotherapy

Improving patient outcomes

Lady smiling outside
What is the test?
A 21-gene genomic test, including 16 cancer-related genes and 5 reference genes1,2
Scientist working in a laboratory

Why test?

To help determine whether an individual diagnosed with early-stage breast cancer may benefit from chemotherapy and to quantify their individual risk of recurrence2,4,5,14,15
Older lady sitting a beach in the sunshine
What information does the test provide?
The Oncotype DX® report provides three key pieces of information to help inform personalised treatment decisions.

References

  1. Paik et al NEJM. 2004,
  2. Paik et al. JCO. 2006,
  3. Sparano and Paik JCO. 2008,
  4. Sparano et al. NEJM. 2018,
  5. Kalinsky. N Engl J Med. 2021.
  6. NCCN Guidelines Insights: Breast Cancer, version 6.2024. https://www.nccn.org/
  7. Andre et al. J Clin Oncol. 2022.
  8. Exact Sciences, Data on file
  9. Nitz et al. Breast Cancer Res Treat. 2017
  10. Curigliano et al. Ann Oncol. 2023.
  11. Loibl et al. Annals of Oncology. 2024 
  12. NICE
  13. IQWiG 2018
  14. IQWiG 2024
  15. Kalinsky et al. SABCS. 2021. GS2-07.
  16. Albain et al. Lancet Oncol. 2010.
Get in touch
Have questions about Oncotype DX®?
Doctor sitting with patient having a discussion.